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Abstract
Background: Patients with testicular germ cell cancer (GCC) have a high cure rate; however, cancer-related fatigue
is the most common complication among patients with GCC undergoing treatment with chemotherapy. Although
exercise is widely recommended, information about the physio-pathological effects of cancer therapy on skeletal
muscle is very limited. Our aim is to evaluate the effects of an individualized program of muscular strength and
endurance with aerobic training on cancer-related fatigue.
Methods/Design: The present study is a randomized controlled trial comparing an individualized program of
muscular strength and endurance with aerobic training compared to a control group. We will conduct this trial in
patients undergoing chemotherapy, recruited by the Department of Oncology of Virgen de la Victoria Hospital
(Málaga). Patients will be included and evaluated before the first cycle of chemotherapy and assigned randomly to
the experimental or control group. Cancer-related fatigue, physical condition and biological samples will be
measured at the beginning and at the end of an 8-week intervention by the same evaluator, who will be unaware
of the allocation of participants to each group. Furthermore, there will be monitoring for 6 months (24 weeks) after
training for all outcome variables.
Discussion: This study hopes to offer patients with GCC an individualized exercise program with aerobic training
for cancer-related fatigue. Such a scheme, if beneficial, could be implemented successfully within public health.
Trial registration: ClinicalTrials.gov Identifier: NCT02433197. Date of registration: 13 April 2015.
Keywords: Testicular cancer, Germ cell cancer, Physical exercise, Cancer-related fatigue, Chemotherapy,
Clinical rules, Metabolomics
* Correspondence: acuesta.var@gmail.com
1Department of Physiotherapy, Faculty of Health Sciences, Instituto de
Investigacion de Biomedicina de Malaga (IBIMA), Universidad de Malaga,
Málaga, Spain
2School of Clinical Science, Faculty of Health, Queensland University of
Technology, Kelvin Grove, QLD, Australia
Full list of author information is available at the end of the article
© 2016 Cuesta-Vargas et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Cuesta-Vargas et al. Trials  (2016) 17:8 
DOI 10.1186/s13063-015-1143-x
Background
Testicular germ cell cancer (GCC) represents 1 % of all
human cancers and its incidence has increased by 1 %
over the last 50 years [1, 2]. In young men, it represents
one of the most malignant forms and is the second com-
monest cause of cancer-related death [1, 2]. Testicular
tumor cell growth constitutes the majority of testicular
malignancies [2]. GCC patients have a high cure rate,
and are sensitive to radiation and chemotherapy, but 5 %
of patients develop resistance to treatment.
Impaired muscle function and cancer-related fatigue
(CRF) are two of the most common complications among
patients in additiounder chemotherapy [3]. Moreover,
early, localized muscular fatigue and severe decondition-
ing are common observations in clinical practice involving
GCC patients undergoing chemotherapy [4]. The cause of
this muscle deconditioning is unknown and although the
effects of antineoplastic drugs have been described in
some detail [4, 5], the way these effects may affect the
phenomenon of CRF is poorly described. With growing
interest in the duality oncology-physical exercise, many
studies are now focused on the implementation of phys-
ical exercise as a complementary intervention to anti-
cancer therapy [6]. Although exercise is widely recom-
mended, information about the physio-pathological effects
of cancer therapy on skeletal musculature is very limited
[7]. Severe and chronic fatigue has been found in 30 % of
long-term GCC survivors many years after the end of pri-
mary treatment [8]. The phenomenon known as “cancer-
related fatigue” is characterized by being more severe,
more distressing and having less chance of relief through
rest than in the general population [9]. Although there are
several questionnaires to assess CRF [10], a complemen-
tary method such as semi-structured [11] could be used.
Treatment with aerobic training in association with
education has been shown to induce clinically very sig-
nificant improvements in breast CRF [4]. In addition, a
program of strength and muscular endurance training
has been shown to attenuate the reductions in fiber size
and strength in healthy subjects and patients [4, 12].
Metabolomics is an emerging discipline, defined as a
multidisciplinary science that requires cooperation be-
tween chemists, biologists and computer scientists. Me-
tabolome is the term used to refer to the complete
inventory of small molecules, non-protein compounds,
such metabolic intermediates, ATP, fatty acids, glucose,
cholesterol, hormones, and other signaling molecules,
and secondary metabolites found in a biological sample
[13, 14]. As such, the metabolome changes continuously,
depending on the activation and interaction of the vari-
ous metabolic pathways inside the cell. It also reflects
the phenotype that can be used to interfere gene function.
Although genomics and proteomics can provide import-
ant information on expected function, metabolomics
provides an immediate snapshot of all biological functions
that reflect current events at a specific time [15].
The primary objective of the study is to investigate
the short- and long-term (6 months) effects of an
individualized program of muscular strength and en-
durance with aerobic training to improve CRF. A sec-
ondary goal is to examine the tolerance of muscular
endurance training started on day 1 of the course of
cancer treatment on muscle deterioration. Further-
more, the effect of the program on metabolomic level
and on various fitness and quality-of-life parameters
will be analyzed to try and establish rules of clinical
prediction by multivariate regressions. The hypothesis
of our study is that a program of muscular strength




The present study is a randomized controlled clinical
trial conforming to Consolidated Standards of Reporting
Trials (CONSORT) guidelines, comparing an individual-
ized program of strength and muscular endurance with
aerobic training versus a control group. All variables will
be measured at the beginning and the end of the 8-week
intervention by the same evaluator, who will be unaware
of the allocation of participants to each group. Further-
more, there will be monitoring for 6 months (24 weeks)
after training for all outcome variables. Evaluations will
be completed in the Area Health Patronage of Sports,
Torremolinos, Spain.
GCC patients between 18 and 45 years who are
due to undergo chemotherapy at the University
Hospital of Málaga will be included in the study.
The sample selection will be among those with per-
formance status (PS) ≤1. Patients will be included
and evaluated before the first cycle of chemotherapy
and assigned to the experimental or control group
randomly by using hidden envelopes. Potential par-
ticipants will be contacted by the study coordinator
and all doubts will be resolved before giving their
written consent from each participant. The expected
flowchart is shown in Fig. 1. The study had ethics
approval from the Comité de Ética de la Investigación
Provincial de Málaga (Consejería de Salud Servicio
Andaluz de Salud, Spain). The principles of the Declaration
of Helsinki are respected.
Treatment
Antineoplastic therapy for GCC will consist of
cisplatin 20 mg/m2 and etoposide 100 g/m2 daily
for 5 days and bleomycin 15,000 IU/m2 weekly.
Three cycles of this combination will be adminis-
tered in 3-week cycles.
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Intervention
The intervention will be an 8-week individualized pro-
gram of muscular strength and endurance with aerobic
training, led by physiotherapists in groups of eight to ten
participants. The 8-week program is a good balance be-
tween the minimum necessary to produce physiological
improvements and the maximum to avoid drop-out. Each
program will be individualized based on the evaluations of
muscular strength and endurance as well as determination
of the aerobic-anaerobic zone transition described in pre-
vious studies [16–19]. Sessions will be of 1 hour duration,
three times a week. Each session will consist of 30 minutes
of strength exercises and 20 minutes of continuous exer-
cises in the aerobic-anaerobic zone transition.
Land-based exercises to improve muscular strength
and endurance will follow the protocol described by An-
dersen and Aagaard [12]. In weeks 1 and 2, participants
carry out 3 sets of 15 repetitions (reps) to become famil-
iar with the exercises. From week 3 onwards, partici-
pants will perform 4 sets of 10 reps. If the participant
can do more than 12 reps, the weight to be lifted will be
increased. All exercises are carried out under supervision
to ensure proper technique and adequate progression.
Aerobic training exercises will be performed using a
cycloergometer [16]. In weeks 1 and 2, participants
perform a low-level intervallic adaptation to adapt to the
experience of fatigue during exercise. For the six
remaining weeks, participants will be instructed to main-
tain a constant rhythm in the cardiac training prescribed
based on an individual test [16] and their gradual adap-
tation to lactate tolerance [6]. If the participant experi-
ences discomfort or severe fatigue during intense
exercise, intensity will be reduced whilst maintaining the
objective whenever possible. Participants will be encour-
aged to participate in all sessions and will be continually
reminded of the importance of adherence in order to
achieve the objectives.
Both groups, intervention and control, receive a
printed decalogue based on common psychosocial issues
for GCC survivors: having cancer and its implications,
stress, distress, uncertainty, fear and anxiety, doubts
about body image, family relations and future prospects
[20]. The control group will be instructed to continue
their current activities and to not objectively increase
levels of physical activity performed during the 8-week
intervention.
Measurements
During the study, course participants will complete
questionnaires and interviews, and tests of physical
Fig. 1 Flow chart of the study
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condition and sampling of tissues and cells will also be
carried out. The primary outcome will be the change in
CRF as measured by the QuickPIPER questionnaire and
also general health and quality of life will be evaluated
by validated scales, as well as an objective assessment of
physical condition by a standardized and validated dyna-
mometer test.
Primary outcomes
The primary outcome will be fatigue, assessed by the
revised CRF QuickPIPER scale [21], with the semi-
structured interview [11] to define CRF phenotype.
Secondary outcomes
Secondary outcome variables were distributed among
the questionnaires, a physical condition test and bio-
logical samples.
Medical and demographic information will be col-
lected about age, marital status, educational level and
surgery for GCC. State of physical and mental health will
be evaluated through the short form (SF-12) [22] and
quality of life (EuroQoL-5D and EuroQoL-VAS) ques-
tionnaires [23]. The study of fatigue will be completed
by the assessment of mood state by POMS (Profile of
Mood States). It is possible to obtain an overall index of
altered mood and seven partial measures: stress/anxiety,
depression/rejection, anger/hostility, vigor/activity, fatigue/
inertia and confusion/bewilderment [24].
A physical condition test will be included to assess iso-
tonic peak strength of knee extension (quadriceps), knee
flexion (hamstring), elbow extension (triceps brachii)
and elbow flexion (biceps brachii) by one dynamomet-
ric measurement instrumented with Powertruck II of
JTECH, following the protocol described by Daniels
and Worthingham [25]. Hand grip strength will be
evaluated by the hydraulic dynamometer JAMAR [26].
Biological samples are taken to determine the immu-
nohistochemical, molecular and systemic changes.
Metabolomic analysis and systemic inflammation will
be measured in 10-ml venous blood samples following
clinical standards. Metabolomics can be used to system-
atically measure the population of biomarkers (metabo-
lites), creating profiles among healthy individuals versus
those with specific diseases [27]. Moreover, metabolo-
mics may provide signs of a metabolic problem or injury
with high precision and less cost than genomics, tran-
scriptomics or proteomics and can, therefore, be a very
suitable technique for generalized scientific research
[28, 29]. Fluid metabolomic analysis is being used suc-
cessfully in cancer [30–33]). Circulating plasma cytokines
will be analyzed using antifreeze, ethylenediaminetetraace-
tate (EDTA). Plasma will be stored at −80 °C until further
analysis. C-reactive protein (CRP), tumor necrosis factor
alpha (TNF-α), interleukin (IL)-6 IL-18, IL-4 and IL-10
will be determined by ELISA (Enzyme-linked Im-
munosorbent Assay) as previously described [34].
Total cholesterol, high-density lipoprotein (HDL),
low-density lipoprotein (LDL) cholesterol, triglycerides,
glucose and insulin will be determined by standard labora-
tory procedures.
Sample size
Version 3.1 G-Power was used to estimate the sample
size and a minimum of 20 subjects per group (10 %
loss) will be required “a priori” to have sufficient
statistical power (80 %), alpha error (0.05) and a clin-
ical effect Cohen’s d = 0.87 in the QuickPIPER scale
of CRF [24].
Statistical treatment
For analysis of the results, a database will be created
using the information collected from participants’
notebooks (questionnaires, interviews, physical tests and
biological tests). Intention-to-treat analysis of all partici-
pants will be developed. After the intervention phase,
descriptive statistics are performed with measures of
central tendency and dispersion of the study variables.
This is followed by inferential analysis by difference
values between the outcome variables in both groups. In
addition, multiple regression analysis of potential predic-
tors is carried out to determine clinical prediction rules
for severe fatigue and other effects of cancer treat-
ment. The size of intergroup effect will be calculated
(Cohen’s d). An effect size <0.2 reflects a negligible
difference, between ≥0.2 and ≤0.5 a small difference,
between ≥0.5 and ≤0.8 a moderate difference, and
≥0.8 a large difference. A value of p <0.05 will be
considered statistically significant. SPSS V 21.0 will be
used in Mac version for data analysis.
Discussion
The study results will be quickly applied in clinical
practice guidelines thanks to the internal and external
validity of the study, whether the hypothesis is ac-
cepted or not. Such a scheme, if beneficial, could be
implemented within public health, after certain re-
quirements are resolved with regard to resistance-
training facilities, with instructors who are properly
educated in order to train cancer patients undergoing
chemotherapy. Patients with testicular GCC are of-
fered an individualized program of muscular strength
and endurance with aerobic training on CRF. In
addition, regression analysis may open up new niche
clinical studies on this question.
Trial status
This study is not yet open for participant recruitment at
the time of submission.
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